The FDA plans to schedule an advisory panel review for Abbott Laboratories' Xience drug-coated coronary stent, an Abbott executive said. The company, which hopes to introduce the device in the U.S. in the first half of 2008, said it's working with the agency to schedule the meeting "as expeditiously as possible."

Related Summaries